Trials / Completed
CompletedNCT06495281
Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients
A Observational Study to Evaluate Effectiveness, Safety of Triple Combination Therapy of Zemidapa and Metformin in Patients With Type 2 DM Who Received Double or Triple Combination Therapy Including DPP4-inhibitor Other Than Gemigliptin
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,044 (actual)
- Sponsor
- LG Chem · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the effectiveness and safety of the triple combination therapy of Zemidapa Tab. and Metformin in patients with type 2 diabete mellitus
Conditions
Timeline
- Start date
- 2023-10-26
- Primary completion
- 2025-12-03
- Completion
- 2025-12-03
- First posted
- 2024-07-10
- Last updated
- 2026-03-11
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06495281. Inclusion in this directory is not an endorsement.